Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Recent studies have revealed extensive genetic diversity both between and within tumours.
This heterogeneity affects key cancer pathways, driving phenotypic variation, and poses a …

Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we …

The proteins encoded by the two major breast cancer susceptibility genes, BRCA1 and
BRCA2, work in a common pathway of genome protection. However, the two proteins work …

Abstract 53BP1 is a chromatin-binding protein that regulates the repair of DNA double-
strand breaks by suppressing the nucleolytic resection of DNA termini,. This function of …

Cancer-associated systemic inflammation is strongly linked to poor disease outcome in
patients with cancer,. For most human epithelial tumour types, high systemic neutrophil-to …

Background Olaparib, a novel, orally active poly (ADP-ribose) polymerase (PARP) inhibitor,
induced synthetic lethality in BRCA-deficient cells. A maximum tolerated dose and initial …

The tumour suppressor breast cancer type 1 susceptibility protein (BRCA1) promotes DNA
double-strand break (DSB) repair by homologous recombination and protects DNA …

DNA polymerase theta (POLθ or POLQ) is synthetic lethal with homologous recombination
(HR) deficiency and is thus a candidate target for HR-deficient cancers. Through high …

Stromal communication with cancer cells can influence treatment response. We show that
stromal and breast cancer (BrCa) cells utilize paracrine and juxtacrine signaling to drive …